乳腺癌中mirna和Wnt信号调控的机制特征及治疗意义。

IF 2.4 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current molecular pharmacology Pub Date : 2023-01-01 DOI:10.2174/1874467216666221017122105

Marjan Talebi, Tahereh Farkhondeh, Mohammad Sadra Harifi-Mood, Mohsen Talebi, Saeed Samarghandian

{"title":"乳腺癌中mirna和Wnt信号调控的机制特征及治疗意义。","authors":"Marjan Talebi, Tahereh Farkhondeh, Mohammad Sadra Harifi-Mood, Mohsen Talebi, Saeed Samarghandian","doi":"10.2174/1874467216666221017122105","DOIUrl":null,"url":null,"abstract":"Breast cancer (BC) is accountable for a large number of female-related malignancies that lead to lethality worldwide. Various factors are considered in the occurrence of BC, including the deregulation of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT). Genetic factors such as microRNAs (miRs) are crucially responsible for BC progression and aggressiveness. Hence, the association of miRs and EMT regulators (e.g., Wnt signaling pathway) is of importance. In the present review, we accurately discussed this interplay (interaction between Wnt and miRs) concerning cell - invasion, -migration, -differentiation, -chemoresistance, survival, and-proliferation, and BC prognosis. The putative therapeutic agents, multidrug resistance (MDR) evade, and possible molecular targets are described as well.","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":"16 5","pages":"530-541"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Mechanistic Features and Therapeutic Implications Related to the MiRNAs and Wnt Signaling Regulatory in Breast Cancer.\",\"authors\":\"Marjan Talebi, Tahereh Farkhondeh, Mohammad Sadra Harifi-Mood, Mohsen Talebi, Saeed Samarghandian\",\"doi\":\"10.2174/1874467216666221017122105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Breast cancer (BC) is accountable for a large number of female-related malignancies that lead to lethality worldwide. Various factors are considered in the occurrence of BC, including the deregulation of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT). Genetic factors such as microRNAs (miRs) are crucially responsible for BC progression and aggressiveness. Hence, the association of miRs and EMT regulators (e.g., Wnt signaling pathway) is of importance. In the present review, we accurately discussed this interplay (interaction between Wnt and miRs) concerning cell - invasion, -migration, -differentiation, -chemoresistance, survival, and-proliferation, and BC prognosis. The putative therapeutic agents, multidrug resistance (MDR) evade, and possible molecular targets are described as well.\",\"PeriodicalId\":10865,\"journal\":{\"name\":\"Current molecular pharmacology\",\"volume\":\"16 5\",\"pages\":\"530-541\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current molecular pharmacology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.2174/1874467216666221017122105\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular pharmacology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/1874467216666221017122105","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

乳腺癌是世界范围内导致死亡的大量与女性相关的恶性肿瘤的罪魁祸首。BC的发生有多种因素，包括癌症干细胞(CSCs)和上皮-间质转化(EMT)的失调。遗传因素如microRNAs (miRs)对BC的进展和侵袭性至关重要。因此，miRs与EMT调控因子(如Wnt信号通路)的关联是非常重要的。在本综述中，我们准确地讨论了这种相互作用(Wnt和miRs之间的相互作用)，涉及细胞侵袭、迁移、分化、化疗耐药、生存和增殖以及BC预后。假定的治疗剂，多药耐药(MDR)逃避，以及可能的分子靶点也进行了描述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mechanistic Features and Therapeutic Implications Related to the MiRNAs and Wnt Signaling Regulatory in Breast Cancer.

Breast cancer (BC) is accountable for a large number of female-related malignancies that lead to lethality worldwide. Various factors are considered in the occurrence of BC, including the deregulation of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT). Genetic factors such as microRNAs (miRs) are crucially responsible for BC progression and aggressiveness. Hence, the association of miRs and EMT regulators (e.g., Wnt signaling pathway) is of importance. In the present review, we accurately discussed this interplay (interaction between Wnt and miRs) concerning cell - invasion, -migration, -differentiation, -chemoresistance, survival, and-proliferation, and BC prognosis. The putative therapeutic agents, multidrug resistance (MDR) evade, and possible molecular targets are described as well.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current molecular pharmacology Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

CiteScore

4.90

自引率

3.70%

发文量

112

期刊介绍： Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes full-length/mini reviews, original research articles and thematic issues on molecular pharmacology. Current Molecular Pharmacology is an essential journal for every scientist who is involved in drug design and discovery, target identification, target validation, preclinical and clinical development of drugs therapeutically useful in human disease.